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Abstract
Background: Preclinical single-photon emission computed tomography (SPECT)/CT imaging studies are hampered by
low throughput, hence are found typically within small volume feasibility studies. Here, imaging and image analysis
procedures are presented that allow profiling of a large volume of radiolabelled compounds within a reasonably short
total study time. Particular emphasis was put on quality control (QC) and on fast and unbiased image analysis.
Methods: 2–3 His-tagged proteins were simultaneously radiolabelled by 99mTc-tricarbonyl methodology and injected
intravenously (20 nmol/kg; 100 MBq; n = 3) into patient-derived xenograft (PDX) mouse models. Whole-body SPECT/CT
images of 3 mice simultaneously were acquired 1, 4, and 24 h post-injection, extended to 48 h and/or by 0–2 h dynamic
SPECT for pre-selected compounds. Organ uptake was quantified by automated multi-atlas and manual segmentations.
Data were plotted automatically, quality controlled and stored on a collaborative image management platform. Ex vivo
uptake data were collected semi-automatically and analysis performed as for imaging data.
Results: >500 single animal SPECT images were acquired for 25 proteins over 5 weeks, eventually generating >3500 ROI
and >1000 items of tissue data. SPECT/CT images clearly visualized uptake in tumour and other tissues even at 48 h
post-injection. Intersubject uptake variability was typically 13% (coefficient of variation, COV). Imaging results correlated
well with ex vivo data.
Conclusions: The large data set of tumour, background and systemic uptake/clearance data from 75 mice for 25
compounds allows identification of compounds of interest. The number of animals required was reduced considerably
by longitudinal imaging compared to dissection experiments. All experimental work and analyses were accomplished
within 3 months expected to be compatible with drug development programmes. QC along all workflow steps, blinding
of the imaging contract research organization to compound properties and automation provide confidence in the data
set. Additional ex vivo data were useful as a control but could be omitted from future studies in the same centre. For
even larger compound libraries, radiolabelling could be expedited and the number of imaging time points adapted to
increase weekly throughput. Multi-atlas segmentation could be expanded via SPECT/MRI; however, this would require an
MRI-compatible mouse hotel. Finally, analysis of nuclear images of radiopharmaceuticals in clinical trials may benefit from
the automated analysis procedures developed.
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Background
In vivo tissue biodistribution of administered drug or
imaging agent candidates is fundamental for their
pharmacological assessment [2], and its evaluation is
required for the translation from in vitro research to
the clinic, see e.g. [3] on radiopharmaceuticals [4].
Medicinal chemists also study compound biodistribu-
tion as an in vivo screen following in vitro tests
(which e.g. confirm target binding). The in vivo as-
sessment focusses on pharmacokinetics, here, bioavail-
ability (concentration in plasma), delivery to and
retention at the target and off-targets, and systemic
clearance over time. This assessment may also include
study of metabolism (DMPK). Experimental methods
can be distinguished [2, 5] e.g. between ex vivo (e.g.
autoradiography [6]) and in vivo, and between label-
free (e.g. Mass Spectrometry Imaging [7]) and labelled
[8]. All these methods have their merits and draw-
backs, but generally, they are all low in throughput
[9]. That low throughput makes these tools unattract-
ive for the screening of larger combinatorial libraries
of compounds. One solution is replacement by in
silico or in vitro screening, but results of current
techniques may not be reliable enough [10]. In vivo
optical imaging may be chosen to increase throughput
[11], but this comes at the cost of limited spatial
resolution and limited quantitation [12]. In this study,
radionuclear imaging has been chosen which provides
quantitative data [13] and for which radiolabelling
automation is possible [14].
Another important consideration is the large number
of animals required for an ex vivo study to cover a suffi-
cient number of time points and to yield statistical sig-
nificance [15]. Humane animal research demands
observing the replacement, reduction and refinement
(3Rs) [16] which includes reducing the number of ani-
mals. This reduction may be achieved by non-invasive
imaging allowing repeated, longitudinal probing in each
animal post-compound administration. As a result, the
reduction factor equals the number of time points. For
example, the NCRI guidelines recommend to use 2 to 3
animals at 5 to 8 time points for a pharmacokinetic
study [17]. This corresponds to 10 to 24 animals in total
with an ex vivo method compared to 2 to 3 animals with
longitudinal in vivo imaging.
One high-throughput 18F positron emission tomography
(PET) study has been reported [18] where 42 compounds
were imaged within 11 days, at up to 3 h pi. The impres-
sive throughput did not include time for image analysis
which in that study was performed manually and thus
would prolong total study time considerably. Therefore,
besides employing longitudinal, multi-animal imaging and
efficient radiolabelling, overall study throughput was
increased in our study by automated image analysis.
Furthermore, quality control was implemented at all rele-
vant steps within the whole process to ensure high data
quality.
In this study, workflows, methods and software have
been developed to allow efficient high-volume compound
screening of 25 proteins by SPECT/CT of a tumour xeno-
graft mouse model. The main interest of this study was to
explore pharmacokinetics and tumour uptake in vivo in a
large panel of compounds with different biologic properties
(e.g. size, charge, and format). Specific goals were to (1)
quantify the test item uptake to the tumour in a patient-
derived xenograph (PDX) mouse model, (2) quantify sys-
temic biodistribution over up to 2 days post-injection (pi),
and (3) confirm last time point imaging data by ex vivo
analysis. The ultimate aim for the medicinal chemists and
pharmacologists was guidance for further drug design
efforts. These efforts, including the preceding, mandatory
in vitro characterization of this compound library, target
validation and animal model validation, will be described
elsewhere by Sanofi affiliated researchers.
Methods
Test compounds
All 25 proteins were designed and synthesized including
a hexahistidine sequence (His-tag) serving two purposes:
improving compound purification and enabling radiola-
belling by the 99mTc-tricarbonyl methodology. These
His-tagged proteins had been used in preceding in vitro
target binding affinity studies. Radiochemistry, imaging
and image analysis staff were blinded to compound
properties except for the individual molecular weights
(14 to 86 kDa).
Radiolabelling
Small aliquots of all 25 proteins were radiolabelled first
for testing, following the recommendations on 99mTc-tri-
carbonyl labelling given in [19]. Subsequently, larger ali-
quots were radiolabelled for imaging. On each imaging
start day, usually 2 or 3 proteins (1.6 to 1.9 nmol of
each) were radiolabelled using 1 Isolink kit (Paul Scher-
rer Institute, Switzerland) and 2.5 GBq 99mTc-pertechne-
tate. After 2 h incubation (3 h for 5 compounds to yield
sufficient labelling efficiency), the product was purified
on a NAP-5 column (GE Healthcare). Aliquots of the
product solution were used for instant thin layer chro-
matography (ITLC) and for size exclusion high-
performance liquid chromatography (HPLC). The re-
mainder of typically 500 to 600 μg was split into 3 por-
tions for injections. See Additional file 1 for further
details.
Reducing renal uptake
To reduce renal uptake of test items, aqueous L-lysine
monohydrochloride (Sigma-Aldrich) solution (pH 7.3)
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mixed with gelofusine (Gelaspan, B. Braun Melsungen,
Germany) was administered [20, 21] as intravenous (iv)
bolus at 4 mL/kg 30 min before radiotracer injection.
Mass doses were 0.1 g/kg gelofusine and 1 g/kg L-lysine.
Animal model
All animal procedures were approved by the Animal
Welfare and Ethical Review Body at Queen Mary Uni-
versity of London and by the UK Home Office in ac-
cordance with EU Directive 2010/63/EU. Female Fox
Chase SCID mice (Charles River, UK) were 6–8 weeks
old on arrival. A first batch of 8 mice was shaved on the
lower back (1 cm2), local anaesthetic cream (lidocaine
and prilocaine) applied, and a≈10 μL fragment of pri-
mary human colon adenocarcinoma tissue (from patient
CR-IGR-034P, tumour collection CReMEC, Oncodesign,
[22]) injected subcutaneously in an intrascapular pos-
ition by trocar under isoflurane anaesthesia. The wound
was closed with spray plaster, and animals were moni-
tored more frequently for 2 days. Once tumours had
grown to 8–10 mm diameter, one animal was sacrificed
each week, the tumour excised and cut into ≈10 μL
pieces for direct passaging into a batch of 20–24 animals
(5 batches in total), following the same inoculation pro-
cedure as above. All animals underwent regular body
weight and tumour size measurements and examinations
for any signs of abnormalities.
Imaging
For each compound, three mice bearing a tumour of
≈0.1 to 0.4 mL were selected randomly, weighed and
bolus iv injected with lysine/gelofusine and the test item
(5 mL/kg, 20 nmol/kg protein, ≈100 MBq) into each of
the lateral tail veins. The delivered test item doses were
calculated from the syringe weights and radioactivity
measurements before and after injections. All three mice
were imaged together on a multi-mouse bed (Minerve,
France) equipped with anaesthesia system (≈2% isoflur-
ane in 1.5 L/min medical oxygen) and warm air ventila-
tion, on a NanoSPECT/CT camera (Bioscan Inc., USA).
The first SPECT image was acquired either at 1 h pi
for 50 min (radiotracer injection and first hour thereafter
without anaesthesia) or as a series of 10 SPECT images
between 10 and 110 min pi (radiotracer injected under
anaesthesia which continued for the dynamic imaging
scan), followed by a CT scan (10 min, 240 projections
with 1 s exposure to 55 kVp X-rays). Further SPECT/CT
images were acquired at 4 and 24 h pi and for some
compounds at 48 h pi (always 50 min SPECT). This
schedule allowed for staggering of 2 or 3 groups of
animals (i.e. compounds) at a time, see Fig. 1.
SPECT and CT images were reconstructed with an
iterative algorithm (HiSPECT, Scivis GmbH, Germany)
and with exact cone beam Filtered Back Projection
(VivoQuant, inviCRO LLC, USA), respectively.
Image analysis
All image processing was performed in VivoQuant 2.0
(inviCRO) and iPACS (inviCRO). Preprocessing included
SPECT/CT coregistration at a voxel size of (0.4 mm)3
and splitting into individual mouse images. An iPACS
script facilitated entering injection doses and body
weights simultaneously for automatic conversion of
image data into absolute radioactivity, percent injected
dose (ID) or standardized uptake value (SUV). A Vivo-
Quant script generated and saved rotating maximum in-
tensity projection (MIP) movies and single-slice images
in all three orientations centred on the tumour ROI with
a chosen colour scale (here 0.2 to 20% ID/mL).
Tissue uptake data from SPECT images were gener-
ated via multi-atlas segmentation: a reference library of
ROIs is built in usually 10 to 20 animals to create an
ROI atlas, which is co-registered to SPECT/CT images.
See Additional file 1 for further details.
Data of all image ROIs (volume, % ID, % ID/mL, SUV)
were saved, then custom plotted via MATLAB script,
e.g. ordered by group (i.e. compound) or by ROI class
(i.e. organ, tissue).
γ-Counting and analysis
Animals were dissected after imaging. Tissue sample
weights were transferred by push-button from the balance
into a spreadsheet template. Decay-corrected counts-per-
minute data of the daily batch of tissue samples (≈100 for 2
compounds) were measured on a γ-counter LKB Wallac
1282 Compugamma within 2 h. All accumulated data of
the whole study were then imported into MATLAB by a
custom-written script linking data points from different
Fig. 1 Examples for scheduling radiolabelling, injections and in
vivo imaging up to 5 h pi (initial part of the whole schedule).
a Two compounds with initial dynamic imaging over 2 h. b Three
compounds with SPECT acquisition starting at 1 h pi
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sources via compound and mouse identifiers. Uptake data
(% ID, % ID/g and SUV) were tabulated and plotted.
Further details including tissue-specific calculations are
described in the Additional file 1.
Quality control procedures and calibrations
Radiolabelling quality control (QC) included (1) ITLC
and HPLC of the product to confirm sufficient radio-
chemical purity (>95%), and (2) measurement of the
radioactivity concentration for the preparation of indi-
vidual radioactivity doses (target≈100 MBq) at a volume
dose of ≈0.2 mL.
Mice were monitored daily to control health status,
and mice were enrolled into the study only in absence of
any abnormalities. QC of tumour volume estimates by
calliper measurements was by SPECT/CT and weighing
excised tumours (target range 0.1 to 0.4 mL).
Radiotracer injection quality was checked by SPECT.
Both the SPECT and CT scanner units passed all manu-
facturer recommended QC procedures checked before
and after the study. Directly after image acquisition and
reconstruction, images were inspected to rule out tech-
nical issues like motion artefacts or poor injections. QC
after image analysis included (1) inspection of all MIP
movies and single slice images to confirm proper pro-
cessing (e.g. coregistration and ROI placements) and
image labelling by subject identifiers (comparing all
images per mouse) and (2) automated detection of
potential outliers in the uptake data.
Ex vivo analysis included automated QC checks on γ-
counting rates falling into the linear range of the
detector and being well above background, and detec-
tion of potential outliers in the tissue weight and uptake
data. Finally, all plots were inspected visually.
Statistical analysis and data plotting
Basic descriptive statistical calculations were performed
in MATLAB R2015b (The MathWorks) and Excel 2013
(Microsoft). Data are reported as mean ± standard devi-
ation (SD) if not noted otherwise. Intersubject variability
was expressed as % COV (coefficient of variation) for
each group of three mice, then taking the median for
each uptake measure over all time points, compounds
and organs. Details and all organ-specific data are given
in the Additional file 1. Bland-Altman analysis and plot-
ting were conducted in Prism 5 (GraphPad Software).
All other plots were prepared in MATLAB.
Results
Radiolabelling
The preparations for imaging had the following study
averages: radiochemical purity = (98.0 ± 1.6) %, activity
= (331 ± 82) MBq in (539 ± 59) μL for three injections.
Animal model
The preparations provided an adequate rolling stock of
animals with tumour xenografts despite the challenge of
an occasionally variable engraftment latency period
apparently not uncommon for PDX models [23]. No
complications were encountered with animal procedures
except for one ulcerating tumour (excluded from study).
Median tumour growth duration was 23 days. Unfore-
seen logistical circumstances required expedition of the
study leading to seven compounds screened in the last
week. The increased demand in animals was met by
accepting some tumours outside the target size range
into the study, see abscissa of left panel in Fig. 4. These
cases are readily identifiable in the available scatter plots,
and no noticeable impact on uptake was found.
Injections and imaging
The phantom-derived quantification calibration factor
obtained before the in vivo study was consistent with
historic data for that scanner and with a confirmatory
calibration check after the in vivo study (within 4%).
Figure 2a shows an example of a SPECT/CT image of
the three mice in the hotel before splitting into individ-
ual animals. Excellent image contrast is obtained in the
SPECT image for tumours, kidneys and bladders. Typ-
ical three-dimensional ROIs are shown in Fig. 2b on a
CT image. Eventually >500 single animal SPECT/CT im-
ages were acquired and analysed for the 25 test com-
pounds within 5 weeks. All images were made available
on the iPACS for manual inspections and archiving.
They were also arranged in annotated slides decks with
A B
Fig. 2 Exemplary images. a “Raw” SPECT/CT image of three mice as
maximum intensity projection. b CT image overlaid with 3D ROI
volumes of whole tumour, heart and kidneys, and of small liver and
muscle portions
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rotating MIP and single-slice image views as SPECT,
SPECT/CT and ROI/CT.
Image analysis produced SPECT data of ≈4000 ROIs.
Examples for SPECT data plots are provided in Fig. 3a,
b. While each plot condenses information from at least
9 SPECT images (three animals, three time points) or
even from ≈500 (all animals, all time points as in Fig. 3a),
the subdivision into tissues and compounds, and the
choice of parameters and various plot types resulted
again in an expansion, here to >1000 plots. This was
managed by tables of contents in PDF slide decks with a
hierarchical folder-structure allowing quick access to any
plot of interest.
Intersubject variability for tumour, heart, kidneys and
liver was 13% for all considered uptake measures (% ID,
% ID/mL, and SUV), ranging from 7% for liver SUV to
19% for heart SUV.
Ex vivo analysis
Circa 1000 tissue samples were collected, weighed and
counted, in typical daily batches of ≈100 or 150 samples.
All data analysis was automated and results were avail-
able in near real-time. However, often a delay of 1–2 days
between sampling and counting was required for very
high activity samples to sufficiently reduce γ-counter
dead-time. Data of such repeat measurements automat-
ically replaced QC-rejected data of the first counting
run.
The final data set was visualized in an automatically
generated PDF slide deck of 172 plots, see examples in
Fig. 3c, d.
Biodistribution data from ex vivo dissection and
SPECT were compared by Bland-Altman analysis, see
Fig. 4 for examples.
Discussion
Study results
Preliminary test radiolabelling proved useful in cases
where insufficient radiolabelling efficiency was solved by
longer incubation. Subsequent radiopreparations for im-
aging all passed QC.
The only problem encountered with the PDX mouse
model was engraftment latency in some animals of the
first passage. Despite an initially reduced choice of ani-
mals for imaging, significant study delays were avoided.
In parallel to regular animal welfare checks, an efficient
















Fig. 3 Exemplary plots of imaging data (top row, mean and SEM error bars for N= 3) and ex vivo data (bottom row, individual data points). a % ID/mL in
left kidney ROIs (all compounds, all time points). b % ID/mL data of compound 17 (all ROIs, all time points). c % ID/g in liver in all animals (≈24 or 48 h pi).
d % ID/g in tumour in all animals (≈24 or 48 h pi)
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continuously adapt the schedule for tumour inoculations
and for optimal selection of animals for imaging.
This study did not attempt to study the effect of lysine
and gelofusine on the biodistribution but rather utilized
this as a blanket method to reduce kidney uptake. Con-
trol experiments to quantitate the absolute or relative
kidney uptake reduction with different radiotracers, e.g.
compounds of different molecular weight, were out of
scope because they would have doubled the number of
experiments. For the presented study, the kidney uptake
data have to be interpreted very carefully. However, since
renal clearance is downstream of delivery to other tis-
sues of interest (e.g. tumour), no significant effect is ex-
pected on these.
The initial study design was based on 13 SPECT im-
ages (of the mouse hotel, N = 3 mice) per compound
starting with dynamic scanning over the first 2 h post-
radiotracer injection and ending at 48 h pi. To cut
costs and to reduce stress to animals, this imaging
schedule was reduced in the final study plan for 18 of
the 25 compounds by removing the last time point
and/or reducing the initial dynamic scanning to a 1 h
“static” image acquisition. Detailed comparisons of
compounds with these 2 different first image acquisi-
tions may need to consider the different durations
under isoflurane anaesthesia.
Image analysis
Region of interest definition methods were chosen to
strike a balance between precision, consistency and effi-
ciency. Concentration (% ID/g, SUV) estimates allow the
use of fixed volume regions. These benefit from gener-
ally low anatomical intersubject variability in preclinical
studies. Examples are liver and kidneys. For liver with its
complex organ shape, a subregional ROI near the organ
centre was used under the assumption of homogeneous
distribution throughout the organ tissue. Kidneys have a
simpler organ shape but can exhibit inhomogeneous
SPECT signal distribution. Therefore, a fixed volume
encompassing ROI was used.
For subcutaneous tumours with their often inhomo-
geneous SPECT signal distribution, inconsistent size and
shape and more variable location, ROIs were generated
manually. Still, for the voxel size and tumour sizes in
this study, erosion of or dilation by a single voxel layer
from the surface of a 3D ROI changes volume estimates
by tens of percents. Therefore, ROI volume estimates
were compared to ex vivo tumour weights as QC. In
cases of large discrepancy, the tumour ROI was revisited
and, if necessary, edited.
Multi-atlas segmentation has proven useful for auto-
mated region identification especially in clinical neuro-
applications [24–27]. To overcome the limitation of
many available software packages designed for clinical
brain imaging, this approach has been implemented and
employed for full and subregion segmentation of other
organs (for whole body distribution and radiation dosim-
etry) in several non-human species. Data variability—due
to factors such as animal positioning, the non-rigidity of
non-brain regions, general shape/distribution outliers
and fluctuating contrast-to-noise—may occasionally
cause segmentation failures, thus requiring strict QC
and manual corrections. Nevertheless, we found in tim-
ing experiments (not shown here) that multi-atlas seg-
mentation followed by user editing of the automatically
generated ROIs still significantly decreases processing
time and observer variability compared to segmenting
regions manually de novo.
Optimal subject number is a challenging question for
preclinical studies. A larger number of mice as normally
used in a dissection study allows for better inference
towards the mouse population compared to the often
reduced number of mice used for imaging. On the one
hand, an animal group size N > 3 is suggested in some
circumstances [15, 28]. On the other hand, longitudinal
imaging of a single mouse removes that intersubject
variability and may allow for a clearer observation e.g. of
Fig. 4 Bland-Altman plots on the difference in tumour data between ex vivo (dissected tissue) and in vivo (SPECT/CT) methods, based on pairs of data from
the same animal. Left panel, tumour weight (ex vivo) and tumour volume (SPECT ROI) (converted to weight assuming tissue density = 1.0 g/mL); right panel,
radiotracer uptake in tumour as % ID (ex vivo from gamma counting and in vivo from SPECT ROI). Bias as dotted line (at −80 mg and +0.14% ID, respectively),
95% agreement interval as pair of bold dotted lines. Values on the abscissa are individual tumour averages over the two measurement methods
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radiotracer kinetics [29]. In this study, statistical analysis
was utilized but not an overarching driver. Rather, the
goal was to achieve sufficient consistency and power in
methodology to identify compounds of interest to be
evaluated more thoroughly in follow-up experiments
and with additional in vitro results at hand. Figure 3a, c
shows that indeed relevant, apparent differences between
compounds are often much greater than intersubject
variability at the chosen group size of three. Ultimately,
the choice of the group size represents a compromise
between statistical needs for in vivo and ex vivo study
design and study aim, logistical implications, cost and
ethics.
Ex vivo
Ex vivo data were acquired to validate the biodistribution
results from imaging which was successful as Bland-
Altman analysis showed. One observation was, however,
that the SPECT tumour ROI volume tended to be signifi-
cantly larger than the ex vivo tumour weight. This discrep-
ancy is likely due to an overestimation of the tumour
volume on the images, and deviation from the assumed
1 g/mL mass density may also play a role. Such an overes-
timated ROI volume likely captures spillover of the
tumour SPECT signal just outside the tumour, an occa-
sional artefact from image reconstruction or smoothing.
This conjecture would explain the good match of tumour
uptake values (% ID) between ex vivo and in vivo measure-
ments and also explain the observed non-equivalent mea-
sures of uptake concentration in tumour (ex vivo % ID/g
versus imaging % ID/mL). As discussed above, the ROI
drawing protocol can be tailored to generate ROIs that
achieve a better match in either % ID (as for tumours in
this study) or % ID/g values between ex vivo dissection
and in vivo imaging data.
Throughput
All experiments from animal model setup to final ana-
lysis took 3 months. This included time for the animal
model setup which could be eliminated in other studies
when using naïve animals, or which might take longer
for certain disease models.
This study design for large proteins included imaging
up to 48 h pi. In hindsight, this time point adds only
limited information to that obtained at 24 h and could
be omitted in a future study of such compounds, making
space in the schedule available for other experiments.
Image analysis of incoming data was done within a day
to create updated study plots. A fortunate benefit was
that image analysis was performed in a later time zone
than data acquisition (GMT→EST), effectively stretch-
ing the working day.
γ-counters are more sensitive than SPECT cameras.
Therefore, the fairly large injected radioactivity dose for
imaging needs to decay considerably to reach the measure-
ment window of a γ-counter. This slows down throughput,
but after successful validation as in this study, ex vivo ana-
lysis could be omitted altogether from future imaging
studies.
High volume imaging generates large amounts of data,
but for preclinical SPECT/CT or PET/CT, this is well
manageable within a contemporary standard information
technology environment.
Subsequent use of the data
Compound ranking, or identifying compounds fulfilling
a set of inclusion criteria, or elimination of poorly per-
forming compounds can be based on algorithms com-
bining several uptake, uptake rate or clearance measures
and limits. A separate paper will apply such an algorithm
in combination with in vitro and in silico measures.
Follow-up in vivo experiments related to pharmacokinet-
ics may be performed on a selected small group of po-
tential lead candidates, e.g. on compound/radiolabel
stability in vivo.
Conclusions
Feasibility and application of high-volume in vivo com-
pound screening by preclinical SPECT/CT and auto-
mated analysis have been demonstrated. Excluding the
animal model setup, the required time for such a study
including a final report is on the order of weeks. Import-
antly, longitudinal imaging reduced the number of ani-
mals three- to fourfold compared to dissection studies,
even 12- to 13-fold when considering the dynamic scans
in this study.
Specific for this study was the compound type, large
proteins, for which (a) a test on intact biological func-
tionality after radiolabelling may be skipped (or replaced
by in vitro target binding affinity measurements of the
His-tagged but unlabelled compounds as done here),
and (b) a “one size fits all” radiolabelling procedure may
work.
The whole process proved efficient and robust. High
confidence in the data set was achieved by (1) blinding
the contract researchers to compound properties, (2)
quality control checks at all stages, (3) transparency of
raw data and analysis procedures and easy access to all
data, and (4) a high automation level in data acquisition
and analysis.
Additional ex vivo data validated the image analysis
approach. While systematic differences in the output pa-
rameters can be observed, these can be corrected for if
desired, and they are not expected to affect the relative
compound ranking. Future studies employing this im-
aging workflow may be streamlined by removing such ex
vivo analysis, although other complementary ex vivo
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techniques like high-resolution autoradiography could
be added.
Outlook
Image acquisition throughput could be increased further
by adapting and/or reducing the number of imaging
time points (as done in this study shortening 0…2 h
dynamic to 1–2 h static scans) and by increasing the
number of animals in the field of view (e.g. with a 3D-
printed 4-bed hotel (inviCRO)). Additional automated
analyses can be integrated into the workflow at little cost
in extra time, for example kinetic modelling (with
image-derived input function) or radiation dosimetry.
Analysis of dual isotope images can be done practically
as quickly as that of single isotope images, but the study
schedule would have to factor in additional radiochemis-
try resources and development time. Additional valuable
information might be extracted from SPECT images
when replacing CT by anatomical MR images with su-
perior soft tissue contrast, ideally in future with a mouse
hotel compatible MRI setup and with simultaneous MR
and nuclear image acquisitions. Finally, analysis of
nuclear images of radiopharmaceuticals in clinical trials
may benefit from the automated analysis procedures
developed.
Additional file
Additional file 1: Detailed descriptions of the radiolabelling procedure,
image analysis, γ-counting procedure and analysis, and intersubject
variability estimation. Further results of the γ-counter calibration, ex
vivo/imaging comparison and intersubject variability. (DOCX 171 kb)
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